Drucker Wealth 3.0 LLC Has $795,000 Position in Eli Lilly and Company $LLY

Drucker Wealth 3.0 LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 36.9% during the 2nd quarter, HoldingsChannel reports. The firm owned 1,010 shares of the company’s stock after acquiring an additional 272 shares during the quarter. Drucker Wealth 3.0 LLC’s holdings in Eli Lilly and Company were worth $795,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Brighton Jones LLC grew its stake in shares of Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC grew its position in Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares during the last quarter. Covestor Ltd grew its position in Eli Lilly and Company by 24.9% in the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock worth $352,000 after purchasing an additional 85 shares during the last quarter. GAMMA Investing LLC grew its position in Eli Lilly and Company by 25.8% in the 1st quarter. GAMMA Investing LLC now owns 18,000 shares of the company’s stock worth $14,866,000 after purchasing an additional 3,696 shares during the last quarter. Finally, Arvest Investments Inc. grew its position in Eli Lilly and Company by 19.9% during the first quarter. Arvest Investments Inc. now owns 1,085 shares of the company’s stock worth $896,000 after buying an additional 180 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on LLY shares. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. Morgan Stanley decreased their price objective on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a report on Friday, October 3rd. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday. Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Finally, HSBC boosted their price target on shares of Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $948.56.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $833.08 on Friday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $937.00. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The stock’s fifty day simple moving average is $742.42 and its 200 day simple moving average is $766.36. The firm has a market cap of $788.47 billion, a price-to-earnings ratio of 54.45, a P/E/G ratio of 1.19 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the previous year, the company earned $3.92 EPS. The firm’s revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson bought 200 shares of Eli Lilly and Company stock in a transaction dated Friday, August 8th. The shares were acquired at an average cost of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director directly owned 9,402 shares of the company’s stock, valued at $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO David A. Ricks bought 1,632 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the acquisition, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.